Tropisetron Protects Against Acetaminophen-Induced Liver Injury via Suppressing Hepatic Oxidative Stress and Modulating the Activation of JNK/ERK MAPK Pathways

Figure 5

Tropisetron attenuates hepatic JNK and ERK expression in APAP-induced hepatic injury. (a) Hepatic p-JNK and JNK protein expression from shams receiving vehicle (sham + C: control; lane 1) or tropisetron (sham + TP3: 3 mg/kg; lane 2), treatment with acetaminophen (APAP: 300 mg/kg) receiving vehicle (APAP + control; lane 3), tropisetron (APAP + TP3: 3 mg/kg; lane 4), tropisetron (APAP + TP1: 1 mg/kg; lane 5), JNK inhibitor SP600125 (APAP + SP: 30 mg/kg; lane 6), or SP600125 plus tropisetron (APAP + SP + TP3; lane 7). (b) Hepatic p-ERK and ERK protein expression from shams receiving vehicle (sham + C: control; lane 1) or tropisetron (sham + TP3: 3 mg/kg; lane 2), treatment with acetaminophen (APAP: 300 mg/kg) receiving vehicle (APAP + control; lane 3), tropisetron (APAP + TP3: 3 mg/kg; lane 4), tropisetron (APAP + TP1: 1 mg/kg; lane 5), ERK1/2 inhibitor PD98059 (APAP + PD: 10 mg/kg; lane 6), or PD98059 plus tropisetron (APAP + PD + TP3; lane 7).

(a)

(b)